Carna Biosciences, Inc.
CBIXF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.49B
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $8.49 Billion |
|---|---|
| Enterprise Value | $9.37 Billion |
| Earnings per Share | $- |
| Beta | 1.49 |
| Outstanding Shares | - |
Return
| Return on Equity | 528.44% |
|---|---|
| Return on Assets | -122.07% |
| Return on Invested Capital | -122.28% |
Valuation & Multiples
| P/E Ratio | -3.26 |
|---|---|
| PEG | 59.58 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 12.86 |
| Enterprise Value to EBIT | -4.72 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | -4.87 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Carna Biosciences, Inc.
61 employees
CEO: Kohichiro Yoshino
Carna Biosciences, Inc., established in Kobe, Japan in 2003, operates as a clinical-stage biopharmaceutical company. Its core focus is on discovering and developing novel drug treatments for significant unmet medical needs, particularly ...